Exchange: NYSEArca·Updated 06:20 PM EDT
News
all
press releases
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights
H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.
Stocktwits
More News
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
Stocktwits
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?
Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.
Stocktwits
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Smart Beta ETF report for XPH
Zacks
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Sector ETF report for XPH
Zacks
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Smart Beta ETF report for XPH
Zacks
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Sector ETF report for XPH
Zacks
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts
Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million.
Stocktwits
Why Did CANF Stock Soar 25% Today?
The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.
Stocktwits
TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint
The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.
Stocktwits

Advertisement|Remove ads.